Ventus’ NLRP3 Inhibitor Shows Potential for CNS Diseases in Phase 1 Trial
Ventus Therapeutics, a US-based clinical-stage biopharmaceutical company leveraging its exclusive structural biology and computational chemistry platform, ReSOLVE™, has disclosed promising
Read more